This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Lumason
- Generic Name
- Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)
- DrugBank Accession Number
- DB14105
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DB14105)
- Weight
- Average: 744.964
Monoisotopic: 744.49172986 - Chemical Formula
- C38H74NaO10P
- Synonyms
- 1,2-dipalmitoyl-sn-glycero-3-phosphorylglycerol sodium salt
- L-DPPG-Na
- R-DPPG-Na
- External IDs
- MG-6060LS
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image LumaSon Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg) Injection, powder, lyophilized, for suspension; Kit Intravenous; Intravesical Bracco Diagnostics Inc 2020-01-15 Not applicable US 
LumaSon Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg) Kit Intravenous; Intravesical Bracco Suisse SA 2015-01-15 Not applicable US Lumason Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg) Injection, powder, lyophilized, for suspension Intravenous; Intravesical Bracco Diagnostics Inc 2021-04-01 Not applicable US
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 841B886EJ7
- CAS number
- 200880-41-7
- InChI Key
- LDWIWSHBGAIIMV-ODZMYOIVSA-M
- InChI
- InChI=1S/C38H75O10P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-37(41)45-33-36(34-47-49(43,44)46-32-35(40)31-39)48-38(42)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h35-36,39-40H,3-34H2,1-2H3,(H,43,44);/q;+1/p-1/t35?,36-;/m1./s1
- IUPAC Name
- sodium (2R)-1-[(2,3-dihydroxypropyl phosphono)oxy]-3-(hexadecanoyloxy)propan-2-yl hexadecanoate
- SMILES
- [Na+].[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Diagnostic Abdominal Injuries / Falls, Accidental / Motor Vehicle Injury / Physical Abuse 1 4 Completed Diagnostic Abdominal Trauma 1 4 Completed Diagnostic Hepatic Disease 1 4 Completed Other Hepatocellular Carcinoma 1 4 Recruiting Diagnostic Renal Malignant Tumor 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for suspension Intravenous; Intravesical Injection, powder, lyophilized, for suspension; kit Intravenous; Intravesical Kit Intravenous; Intravesical - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5686060 No 1997-11-11 2017-11-11 US US10232061 No 2019-03-19 2038-07-06 US US10335502 No 2019-07-02 2038-07-06 US US11723869 No 2019-05-15 2039-05-15 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000119 mg/mL ALOGPS logP 8.32 ALOGPS logP 10.94 Chemaxon logS -6.8 ALOGPS pKa (Strongest Acidic) 1.89 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 151.65 Å2 Chemaxon Rotatable Bond Count 40 Chemaxon Refractivity 194.19 m3·mol-1 Chemaxon Polarizability 88.81 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 335.0591676 predictedDarkChem Lite v0.1.0 [M+H]+ 334.3078676 predictedDarkChem Lite v0.1.0 [M+Na]+ 333.6162676 predictedDarkChem Lite v0.1.0
Drug created at June 21, 2018 16:23 / Updated at July 12, 2021 03:34